大成生化科技(00809.HK)預計年度淨溢利約36億至40億港元
格隆匯2月29日丨大成生化科技(00809.HK)發佈公吿,公司預計截至2023年12月31日止年度錄得淨溢利(不包括税項影響),範圍約在36億港元至40億港元,相對去年同期則錄得淨虧損(不包括税項影響)約15.74億港元。
集團的已終止經營業務即指大成糖業控股有限公司(一家於聯交所主板上市的公司,股份代號:03889)及其附屬公司的營運,於2023年12月21日集團完成出售大成糖業集團後不再成為集團的一部分。
有關明顯改善乃主要由於集團預期確認下列各項所致:(i)債務重組安排所產生的本年度一次性所得不少於約4,000,000,000港元;(ii)本年度大成糖業完成的一次性所得不少於約200,000,000港元;(iii)就公司於2015年10月向現代農業產業投資有限公司發行的可換股債券到期日由經延長到期日2023年6月15日進一步延長至2025年9月30日而於本年度的一次性所得不少於約300,000,000港元;及(iv)於本年度終止確認公司間接全資附屬公司哈爾濱大成生物科技有限公司的資產及負債的一次性所得不少於約400,000,000港元。
因此,與去年同期相比,預期集團於本年度的年度業績將錄得明顯改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.